Outlook 2021: Medtechs Must Look To Late 2021 And 2022 For A Return To Normal Times
Medtech is as attractive as it has ever been says Jefferies Healthcare
Executive Summary
Delivering innovation is still the driving force for medtechs intent on growing in the market, regardless of COVID-19, the disruptive effects of which have intensified with the appearance of new variants, says Jefferies Healthcare equity analyst Raj Denhoy.
You may also be interested in...
Pandemic Perspectives: A Lasting Impact On Medtech, But Not Dealmaking
The COVID-19 pandemic has fundamentally changed health care and the life sciences, KPMG analyst Kristin Pothier concludes in a new report on the medtech investment outlook.
Boston Scientific Gives Up On Lotus Edge TAVR
The company is recalling all unused Lotus Edge inventory and will stop developing the Lotus platform while shifting resources to support its Acurate neo2 transcatheter aortic valve system. The decision will cost the company up to $300m.
No MRA Means Switzerland’s Seamless IVDs Trade With The EU Is At An End
The EU’s full implementation of the In Vitro Diagnostic Regulation on 26 May has put the Swiss IVD industry on a "third country" footing with the EU, as happened in 2021 for medical devices. The two parties’ mutual recognition agreement for all medtech products has ceased to apply. A renewed MRA is not likely for several years.